PAVmed Inc. (NSDQ:PAVMU) said today that it inked an exclusive licensing agreement with academic institutions to develop and commercialize antibiotic-eluting resorbable ear tubes based on an aqueous silk technology designed by the institutions.
The licensing deal includes agreements with Tufts University, Massachusetts Eye & Ear Infirmary and Massachusetts General Hospital, who developed the aqueous silk technology.
As many as 1 million children annually undergo pediatric surgery to place metal, plastic, or latex bilateral ear tubes to ventilate and drain the middle ear as a means to relieve persistent ear infections (otitis media) or middle ear fluid collections (effusions), the company said. The procedure is the most common pediatric surgical procedure in the U.S., according to PAVmed.
Get the full story at our sister site, Drug Delivery Business News.